Republished from the official company website. Author and content source: Crystal Pharmatech.
Learn how to design a drug-excipient compatibility study for oral solid dosage forms using binary or multi-component mixtures and accelerated conditions.
Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.
A Guide to Study Design, Storage Conditions, Time Points, and Defensible Scope for Oral Solid Dosage Forms.
Drug-excipient compatibility testing is a pivotal preformulation study that identifies chemical or physical interactions between an API and prospective excipients. The primary study-design decision is whether to use binary mixtures, multi-component mixtures, or a staged combination of both in the study design. Binary studies pair the API with a single excipient at a time to isolate and pinpoint individual incompatibilities. Multi-component studies combine the API with multiple excipients or test a full prototype blend to evaluate multi-component interactions under realistic formulation conditions. Most oral solid dosage programs use a two-step approach: binary studies first to screen and rank excipients, followed by a multi-component study to confirm the stability of the selected prototype blend. Studies typically run for 4 to 8 weeks at 40 °C/75% RH.
A binary compatibility study pairs the API with one excipient at a time, so any observed change can be traced back to that individual excipient. A multi-component study combines the API with multiple excipients, or with a full prototype blend, to evaluate how the components behave in combination rather than in isolation. In short, a binary study helps identify which excipient the API may interact with, while a multi-component study assesses whether the actual formulation remains stable.
Both study designs use elevated temperature and humidity to accelerate potential interactions, then track chemical and physical changes over time. The key differences are summarized below:
Table 1.
| Binary Mixture | Multiple Mixture | |
| Composition | API + Single Excipient | API + Multiple Excipients / Prototype Blend |
| Question it answers | Which specific excipient reacts with the API? | Whether the actual formulation holds up? |
| Sensitivity | High attribution: any observed degradation traces to one excipient | Captures synergy: Detects combination-driven effects (e.g., moisture redistribution, pH shifts). |
| Trade-off | May miss combination effects present in the real blend | Harder to attribute degradation to a single cause |
| Typical use | Early screening to rank and eliminate incompatible excipients | Confirmation of the selected prototype before formal stability |
Two established fundamental designs anchor standard industry practice:
1. Serajuddin classic screening model (1999)
The classic screening model, introduced by Serajuddin and colleagues at Bristol-Myers Squibb, stores binary drug-excipient blends (about 200 mg per vial, with the drug-to-excipient ratio reflecting the intended final formulation) with 20% added water in closed glass vials at 50 °C, and analyzes them for chemical and physical stability after 1 and 3 weeks.¹ It was designed specifically to identify interaction risks driven by excipient chemistry, drug-to-excipient ratio, moisture, microenvironmental pH, temperature, and light at the outset of development, before they become unexpected issues during long-term stability studies.
2. Miniaturized High-Throughput Approach
Modern laboratories adapt this approach into a miniaturized, higher-throughput format: binary mixtures are prepared in 96-well microplates under defined temperature and humidity combinations (for example, 40 to 50 °C and 10% to 75% RH), analyzed by fast-gradient HPLC, and evaluated using statistical experimental design to resolve the effects of time, temperature, humidity, and excipient.² This approach trades blend size for analytical speed and statistical power, making it particularly useful when the available API is limited or the excipient screening pool is large.
Table 2.
| Design element | Serajuddin Classic Screening Model (1999) | Miniaturized High-Throughput Approach (published) |
| Format | Binary blends in closed glass vials | Binary mixtures in 96-well microplates |
| Blend weight / ratio | ~200 mg per vial at target formulation ratio | Approximately 1:100 drug: excipient |
| Moisture | 20% added water | Controlled relative humidity (e.g, 10% and 75% RH) |
| Temperature | 50 °C | 40 to 50 °C |
| Time points | 1 and 3 weeks | 1 to 4 weeks |
| Analysis | Chemical and physical stability (assay, degradants, appearance, thermal analysis) | Fast-gradient HPLC with statistical experimental design |
Note: Parameters as reported in the cited studies. A drug-only control is run alongside to separate excipient effects from intrinsic degradation. Whichever base design is used, a multi-component study on the selected prototype blend follows to confirm the real formulation, and a photostability arm per ICH Q1B is added where light exposure is relevant.3
The primary condition is the ICH accelerated condition of 40 °C/75% RH. It is run under both open and closed conditions so that moisture-driven interactions can be captured. A 25 °C/60% RH arm provides a lower-stress comparator. A dry thermal arm, using elevated temperature without added humidity, helps separate purely thermal effects from moisture-mediated pathways. Published high-throughput studies have used temperatures of 40 to 50 °C and relative humidities ranging from approximately 10% to 75% RH to evaluate the effects of temperature, humidity, and excipient on degradation kinetics.
Typical time points are initial, 2, 4, and 8 weeks. Four weeks is generally sufficient to detect clear chemical incompatibilities, while extending to 8 weeks provides additional confidence for borderline interactions or slower degradation pathways. The principle mirrors forced degradation: applying enough stress and time to reveal a meaningful interaction, without pushing conditions so far that artifacts dominate. A concurrent drug-only control is essential so that degradation intrinsic to the API is not misattributed to an excipient.
A robust compatibility study for oral tablets should cover the primary functional classes that make up the formulation, because each class carries characteristic interaction risks. The six below are the standard set:
The point of covering all six is that incompatibilities are often class-specific and predictable in type, if not in magnitude. Screening one filler while skipping the lubricant, for example, leaves a known high-risk interaction untested.
Incompatibility is identified by comparing blending data directly against concurrent controls:
The staging logic follows from this: binary screening isolates which excipient is responsible for an observed interaction, and a multi-component study on the prototype then confirms that the selected combination remains stable in the form it will actually take.
Binary First: when the goal is to screen and rank a set of candidate excipients and to attribute any incompatibility to a specific component. This is the standard early-stage approach.
Multi-component First: when a prototype formulation is already defined and the goal is to confirm multi-component stability (moisture redistribution, microenvironmental pH, competing reactions).
Both (Combined): Recommended for most solid dosage programs, particularly for high-risk APIs (reactive functional groups, moisture-sensitive APIs, or complex formulations).
Crystal Pharmatech designs and runs drug-excipient compatibility studies as part of integrated preformulation and formulation development. We scope the design to the program: binary screens to rank excipients and isolate incompatibilities, multi-component studies to confirm a prototype blend, and staged programs that combine both for higher-risk compounds. Studies are run under monitored temperature, humidity, and light conditions that comply with ICH guidelines, with HPLC related-substances analysis, appearance, and physical characterization read against concurrent controls.
Because our preformulation, analytical, and formulation teams operate as one workflow through the Mol2Med™ approach, a compatibility signal flags a formulation decision directly, guiding excipient selection and the prototype that moves into stability, rather than surfacing as a surprise on formal stability later.
Learn more:Excipient Selection and Compatibility Studies
Related in this series: A Section by Section Guide, and Forced Degradation Studies for Candidate Selection.
A: Start with binary studies to screen and rank candidate excipients and attribute any incompatibility to a specific component, then run a multi-component study on the selected prototype to confirm the real blend is stable. For high-risk APIs, plan both from the outset.1
A: A common design stresses blends at 40 °C/75% RH (open and closed) with a 25 °C/60% RH comparator and a dry thermal arm, sampling at initial, 2, 4, and 8 weeks.1Add a photostability arm per ICH Q1B where light exposure is relevant.3Always run a drug-only control.
A: Cover the functional classes in the intended formulation: filler, binder, disintegrant, lubricant, glidant, and any pH modifier or other functional excipient. Use HPLC related-substances and assay as the primary readouts, with appearance and XRPD as supporting signals, and include both drug-only and drug-free controls.
A: Most studies run 4 to 8 weeks at accelerated conditions. Four weeks is often enough to flag a clear incompatibility; 8 weeks adds confidence for borderline or slow-reacting cases.
Authored By the Crystal Pharmatech Formulation and Analytical and Marketing Teams